![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SYCE1L |
Gene summary for SYCE1L |
![]() |
Gene information | Species | Human | Gene symbol | SYCE1L | Gene ID | 100130958 |
Gene name | synaptonemal complex central element protein 1 like | |
Gene Alias | MRP2 | |
Cytomap | 16q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A8MT33 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
100130958 | SYCE1L | male-WTA | Human | Thyroid | PTC | 5.90e-08 | 6.94e-02 | 0.1037 |
100130958 | SYCE1L | PTC01 | Human | Thyroid | PTC | 4.70e-08 | 2.57e-01 | 0.1899 |
100130958 | SYCE1L | PTC03 | Human | Thyroid | PTC | 2.66e-02 | 1.11e-01 | 0.1784 |
100130958 | SYCE1L | PTC05 | Human | Thyroid | PTC | 2.24e-25 | 1.08e+00 | 0.2065 |
100130958 | SYCE1L | PTC06 | Human | Thyroid | PTC | 3.66e-27 | 8.52e-01 | 0.2057 |
100130958 | SYCE1L | PTC07 | Human | Thyroid | PTC | 6.63e-27 | 7.76e-01 | 0.2044 |
100130958 | SYCE1L | ATC09 | Human | Thyroid | ATC | 2.35e-04 | 2.58e-01 | 0.2871 |
100130958 | SYCE1L | ATC1 | Human | Thyroid | ATC | 6.34e-03 | 2.65e-01 | 0.2878 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070595 | Thyroid | PTC | chromosome segregation | 146/5968 | 346/18723 | 2.99e-05 | 2.87e-04 | 146 |
GO:00482855 | Thyroid | PTC | organelle fission | 188/5968 | 488/18723 | 9.64e-04 | 5.77e-03 | 188 |
GO:00988135 | Thyroid | PTC | nuclear chromosome segregation | 114/5968 | 281/18723 | 1.21e-03 | 6.94e-03 | 114 |
GO:00002804 | Thyroid | PTC | nuclear division | 167/5968 | 439/18723 | 3.27e-03 | 1.60e-02 | 167 |
GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
GO:009881312 | Thyroid | ATC | nuclear chromosome segregation | 145/6293 | 281/18723 | 3.06e-10 | 8.61e-09 | 145 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
GO:000028011 | Thyroid | ATC | nuclear division | 207/6293 | 439/18723 | 1.98e-09 | 4.80e-08 | 207 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYCE1L | SNV | Missense_Mutation | c.73N>A | p.Ser25Thr | p.S25T | A8MT33 | protein_coding | tolerated(0.09) | benign(0.021) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SYCE1L | SNV | Missense_Mutation | c.386N>G | p.Asp129Gly | p.D129G | A8MT33 | protein_coding | deleterious(0.02) | possibly_damaging(0.513) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SYCE1L | SNV | Missense_Mutation | novel | c.337G>C | p.Glu113Gln | p.E113Q | A8MT33 | protein_coding | deleterious(0.01) | benign(0.167) | TCGA-VS-A9UZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SYCE1L | SNV | Missense_Mutation | novel | c.211G>C | p.Glu71Gln | p.E71Q | A8MT33 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-ZJ-AAXN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SYCE1L | SNV | Missense_Mutation | rs538039690 | c.455G>A | p.Arg152His | p.R152H | A8MT33 | protein_coding | deleterious(0.03) | possibly_damaging(0.706) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYCE1L | SNV | Missense_Mutation | c.116N>G | p.Gln39Arg | p.Q39R | A8MT33 | protein_coding | deleterious(0.01) | possibly_damaging(0.637) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
SYCE1L | SNV | Missense_Mutation | c.8N>C | p.Gly3Ala | p.G3A | A8MT33 | protein_coding | tolerated(0.51) | benign(0.104) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SYCE1L | SNV | Missense_Mutation | c.581G>A | p.Gly194Glu | p.G194E | A8MT33 | protein_coding | deleterious(0.04) | possibly_damaging(0.548) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SYCE1L | SNV | Missense_Mutation | novel | c.212A>G | p.Glu71Gly | p.E71G | A8MT33 | protein_coding | deleterious(0) | possibly_damaging(0.768) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYCE1L | SNV | Missense_Mutation | novel | c.399N>T | p.Gln133His | p.Q133H | A8MT33 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |